Liver cancer is the most common malignant tumor of the digestive system, which is a serious threat to people’s life and health. There are primary liver cancer and metastatic liver cancer. Most primary liver cancers in China have hepatitis B background, and in recent years, there is an obvious increasing trend of primary liver cancers with hepatitis C background. The prognosis of liver cancer is generally considered to have a very important relationship with early detection, which the author does not deny. However, for some patients with late detection and severe degree, the appropriate treatment plan can greatly affect the survival time of patients. 1, Surgery is the main treatment: Surgery is an important treatment method for primary liver cancer and is the first choice for treatment. For some larger tumors located around important ducts, complete surgical resection can significantly improve the survival time of patients. The application of cryovascular freezing and resuscitation duct reconstruction technology and biliary tract reconstruction technology can greatly improve the resection rate of tumors and ensure safe surgical margins. For patients with concomitant cancerous emboli, the key in surgery is to prevent tumor dissemination. Healthy hemihepatoprotective techniques can be applied for prevention. There is no shortage of patients with longer-term survival after complete resection of tumor and cancer embolus. Metastatic liver cancer is firstly determined whether it is accompanied by metastasis from other organs, and metastatic liver cancer of the gastrointestinal tract should be managed with aggressive surgical treatment. The clinical program design process needs to pay extreme attention to the first surgical design to completely remove the tumor, and of course, it also needs to have the preparation for second or even third treatment, through which some patients can obtain long-term survival. 2, pay attention to local treatment techniques such as radiofrequency Some studies have shown that for tumors less than 3cm in diameter, radiofrequency can achieve complete destruction, and the effect is similar to surgical resection, which provides an extremely important clinical approach. It can be considered that for recurrent tumors less than 3 cm, it should be applied as the preferred treatment option. Local treatment also includes local radiotherapy techniques. The application of precise radiotherapy techniques, gamma knife, etc. can shrink the tumor to some extent, which is more effective in combination with chemotherapy. 3, TACE and other methods sometimes have considerable efficacy. For patients with hepatocellular carcinoma who cannot be surgically resected, and for patients who cannot or do not want to undergo surgery for specific reasons (e.g. advanced age, severe cirrhosis, etc.), radiation interventional therapy can be the first choice among non-surgical treatments. 4, Molecular targeted therapy can improve patient survival Sorafenib is a multi-target, multi-kinase inhibitor that can exert dual inhibition and multi-target blockade against primary hepatocellular carcinoma. Several randomized, double-blind, parallel-controlled international multicenter phase III clinical studies have shown that sorafenib can delay the progression of HCC and significantly prolong the survival of patients with advanced disease. It is entirely possible to improve the survival rate and survival time of patients with hepatocellular carcinoma only through unremitting efforts.